• 1.

    Henry JB. Clinical enzymology. In: Henry JB, ed. Clinical diagnosis and management by laboratory methods. Philadelphia: WB Saunders Co, 1996;281284.

    • Search Google Scholar
    • Export Citation
  • 2.

    Milne EM, Doxey DL. Lactate dehydrogenase and its isoenzymes in the tissues and sera of clinically normal dogs. Res Vet Sci 1987;43:222224.

    • Search Google Scholar
    • Export Citation
  • 3.

    Ferraris AM, Guintini P, Gaetani GF. Serum lactic dehydrogenase as a prognostic tool in non-Hodgkin's lymphomas. Blood 1979;54:928932.

  • 4.

    Dumontet C, Drai J & Bienvenu J, et al. Profiles and prognostic values of LDH isoenzymes in patients with non-Hodgkin's lymphoma. Leukemia 1999;13:811817.

    • Search Google Scholar
    • Export Citation
  • 5.

    Kornberg A, Polliack A. Serum lactic dehydrogenase (LDH) levels in acute leukemia: marked elevations in lymphoblastic leukemia. Blood 1980;56:351355.

    • Search Google Scholar
    • Export Citation
  • 6.

    Muller CP, Seik L. Increased activity of a basic LDH 5-related isoenzyme in cells derived from chronic myeloid leukemia. Anticancer Res 1989;9:559565.

    • Search Google Scholar
    • Export Citation
  • 7.

    Dimopoulos MA, Barlogie B & Smith TL, et al. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991;115:931935.

    • Search Google Scholar
    • Export Citation
  • 8.

    Venkitaraman R, Johnson B & Huddart RA, et al. The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int 2007;100:3032.

    • Search Google Scholar
    • Export Citation
  • 9.

    Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006;9:425434.

    • Search Google Scholar
    • Export Citation
  • 10.

    Nicolaides C, Fountzilas G & Zoumbos N, et al. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology 1998;55:405415.

    • Search Google Scholar
    • Export Citation
  • 11.

    Bonadonna G, Jotti GS. Prognostic factors and response to treatment in non-Hodgkin's lymphomas. Anticancer Res 1987;7:685694.

  • 12.

    Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ‘high-risk' disease? Blood 1994;83:11651173.

  • 13.

    Tomita N, Kodama F & Sakai R, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 2000;38:335343.

    • Search Google Scholar
    • Export Citation
  • 14.

    Rotenberg Z, Weinberger I & Fuchs Y, et al. Elevation of serum lactic dehydrogenase levels as an early marker of occult malignant lymphoma. Cancer 1984;54:13791381.

    • Search Google Scholar
    • Export Citation
  • 15.

    Coiffier B, Lepage E. Prognostic factors in large-cell lymphomas. Leuk Lymphoma 1993;10:5760.

  • 16.

    Zanatta R, Abate O & D'Angelo A, et al. Diagnostic and prognostic value of serum lactate dehydrogenase (LDH) and LDH isoenzymes in canine lymphoma. Vet Res Commun 2003;27:449452.

    • Search Google Scholar
    • Export Citation
  • 17.

    Hadden AG, Cotter SM & Rand W, et al. Efficacy and toxicosis of VELCAP-C treatment of lymphoma in cats. J Vet Intern Med 2008;22:153157.

  • 18.

    von Euler HP, Ohrvik AB, Eriksson SK. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs. Res Vet Sci 2006;80:1724.

    • Search Google Scholar
    • Export Citation
  • 19.

    Nakamura N, Momoi Y & Watari T, et al. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. J Vet Med Sci 1997;59:957960.

  • 20.

    Hahn KA, Freeman KP & Barnhill MA, et al. Serum alpha 1-acid glycoprotein concentrations before and after relapse in dogs with lymphoma treated with doxorubicin. J Am Vet Med Assoc 1999;214:10231025.

    • Search Google Scholar
    • Export Citation
  • 21.

    von Euler H, Einarsson R & Olsson U, et al. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. J Vet Intern Med 2004;18:696702.

    • Search Google Scholar
    • Export Citation
  • 22.

    Vail DM, Young KM. Canine lymphoma and lymphoid leukemia. In: Withrow SJ, Vail DM, eds. Withrow & MacEwen's small animal clinical oncology. 4th ed. Philadelphia: WB Saunders Co, 2007;699722.

    • Search Google Scholar
    • Export Citation
  • 23.

    Raskin RE. Lymphoid system. In: Raskin RE, Meyer DJ, eds. Atlas of canine and feline cytology. Philadelphia: WB Saunders Co, 2001;111.

  • 24.

    Jeglum KA. Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Vet Clin North Am Small Anim Pract 1996;26:7385.

    • Search Google Scholar
    • Export Citation
  • 25.

    Marconato L, Bonfanti U & Stefanello D, et al. Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference? Vet Comp Oncol 2008;6:8089.

    • Search Google Scholar
    • Export Citation
  • 26.

    Keller ET, MacEwen EG & Rosenthal RC, et al. Evaluation of prognostic factors and sequential chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289295.

    • Search Google Scholar
    • Export Citation
  • 27.

    Teske E, van Heerde P & Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:17221728.

    • Search Google Scholar
    • Export Citation
  • 28.

    Khanna C, Lund EM & Redic KA, et al. Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma. J Am Vet Med Assoc 1998;213:985990.

    • Search Google Scholar
    • Export Citation
  • 29.

    Jagielski D, Lechowski R & Hoffmann-Jagielska M, et al. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998–2000). J Vet Med A Physiol Pathol Clin Med 2002;49:419424.

    • Search Google Scholar
    • Export Citation
  • 30.

    Abbo AH, Lucroy MD. Assessment of anemia as an independent predictor of response to chemotherapy and survival in dogs with lymphoma: 96 cases (1993–2006). J Am Vet Med Assoc 2007;231:18361842.

    • Search Google Scholar
    • Export Citation
  • 31.

    Miller AG, Morley PS & Rao S, et al. Anemia is associated with decreased survival time in dogs with lymphoma. J Vet Intern Med 2009;23:116122.

  • 32.

    Skipper HE, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res 1970;30:18831897.

Advertisement

Clinical relevance of serial determinations of lactate dehydrogenase activity used to predict recurrence in dogs with lymphoma

View More View Less
  • 1 Clinica Veterinaria L'Arca, Vico Cacciottoli 46, 80129 Napoli, Italy.
  • | 2 Clinica Veterinaria L'Arca, Vico Cacciottoli 46, 80129 Napoli, Italy.
  • | 3 Clinica Veterinaria L'Arca, Vico Cacciottoli 46, 80129 Napoli, Italy.
  • | 4 Clinica Veterinaria L'Arca, Vico Cacciottoli 46, 80129 Napoli, Italy.
  • | 5 Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland.

Abstract

Objective—To evaluate whether serial determinations of serum lactate dehydrogenase (LDH) activity in dogs with lymphoma could be used to predict outcome and assist in early recognition of disease progression.

Design—Prospective cohort study.

Animals—50 dogs with lymphoma.

Procedures—LDH activity was determined in dogs with newly diagnosed lymphoma or that had not received treatment. The LDH activity was measured at time of initial diagnosis, at completion of chemotherapy, and at 1, 3, and 6 months after chemotherapy. Treatment response and recurrence were recorded. At the end of chemotherapy and at each time point thereafter, the proportion of dogs in complete remission with elevated LDH activity was compared between dogs that did or did not have recurrence within the successive 45 or 90 days. Use of the LDH activity at admission to predict disease-free and survival intervals was evaluated.

Results—The proportion of dogs in complete remission with increased LDH activity at completion of chemotherapy and at 1 month after chemotherapy with recurrence during the successive 45 days was significantly higher (3/9 and 7/9 dogs, respectively) than the proportion of dogs without recurrence (0/32 and 1/26 dogs, respectively). At 3 or 6 months, only 1 dog without recurrence within 45 days had increased LDH activity. Increased LDH activity at time of diagnosis was not associated with disease-free and survival intervals.

Conclusions and Clinical Relevance—Determination of LDH activity may help with identifying episodes of recurrence in dogs with lymphoma. Anticipation of recurrence is an appropriate reason to begin rescue treatment.

Abstract

Objective—To evaluate whether serial determinations of serum lactate dehydrogenase (LDH) activity in dogs with lymphoma could be used to predict outcome and assist in early recognition of disease progression.

Design—Prospective cohort study.

Animals—50 dogs with lymphoma.

Procedures—LDH activity was determined in dogs with newly diagnosed lymphoma or that had not received treatment. The LDH activity was measured at time of initial diagnosis, at completion of chemotherapy, and at 1, 3, and 6 months after chemotherapy. Treatment response and recurrence were recorded. At the end of chemotherapy and at each time point thereafter, the proportion of dogs in complete remission with elevated LDH activity was compared between dogs that did or did not have recurrence within the successive 45 or 90 days. Use of the LDH activity at admission to predict disease-free and survival intervals was evaluated.

Results—The proportion of dogs in complete remission with increased LDH activity at completion of chemotherapy and at 1 month after chemotherapy with recurrence during the successive 45 days was significantly higher (3/9 and 7/9 dogs, respectively) than the proportion of dogs without recurrence (0/32 and 1/26 dogs, respectively). At 3 or 6 months, only 1 dog without recurrence within 45 days had increased LDH activity. Increased LDH activity at time of diagnosis was not associated with disease-free and survival intervals.

Conclusions and Clinical Relevance—Determination of LDH activity may help with identifying episodes of recurrence in dogs with lymphoma. Anticipation of recurrence is an appropriate reason to begin rescue treatment.

Contributor Notes

Dr. Marconato's present address is Animal Oncology and Imaging Center, Rothusstrasse 2, Hünenberg, Switzerland.

Address correspondence to Dr. Marconato (marconato@aoicenter.ch).